Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.
作者信息
Heo Jeong
出版信息
Korean J Hepatol. 2011 Sep;17(3):180-2. doi: 10.3350/kjhep.2011.17.3.180.
Abstract
摘要
相似文献
1
Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.
Korean J Hepatol. 2011 Sep;17(3):180-2. doi: 10.3350/kjhep.2011.17.3.180.
2
The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
Korean J Hepatol. 2012 Mar;18(1):29-31. doi: 10.3350/kjhep.2012.18.1.29. Epub 2012 Mar 22.
3
Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
Clin Mol Hepatol. 2013 Mar;19(1):26-8. doi: 10.3350/cmh.2013.19.1.26. Epub 2013 Mar 25.
4
[Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
Zhonghua Gan Zang Bing Za Zhi. 2014 Oct;22(10):772-3.
5
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
Clin Mol Hepatol. 2012 Sep;18(3):268-71. doi: 10.3350/cmh.2012.18.3.268. Epub 2012 Sep 25.
6
[Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].
Korean J Gastroenterol. 2012 Nov;60(5):273-4. doi: 10.4166/kjg.2012.60.5.273.
7
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Aliment Pharmacol Ther. 2013 Feb;37(4):491. doi: 10.1111/apt.12175.
8
Hepatitis C virus: five-year follow-up of patients with sustained virological response.
Rev Esp Enferm Dig. 2011 Feb;103(2):53-5. doi: 10.4321/s1130-01082011000200001.
9
Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Mar 1;38(1):25-33. doi: 10.1515/prilozi-2017-0003.
10
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
Hepatology. 2009 Jun;49(6):2125; author reply 2125-6. doi: 10.1002/hep.22826.
本文引用的文献
1
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.
Korean J Hepatol. 2011 Sep;17(3):183-8. doi: 10.3350/kjhep.2011.17.3.183.
2
[Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Korean J Gastroenterol. 2011 Mar;57(3):173-9. doi: 10.4166/2011.57.3.173.
3
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.
World J Gastroenterol. 2011 Jan 28;17(4):493-8. doi: 10.3748/wjg.v17.i4.493.
4
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Gastroenterology. 2010 Nov;139(5):1593-601. doi: 10.1053/j.gastro.2010.07.009. Epub 2010 Jul 14.
5
[Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
Korean J Hepatol. 2009 Mar;15(1):70-9. doi: 10.3350/kjhep.2009.15.1.70.
6
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
Hepatology. 2009 Mar;49(3):729-38. doi: 10.1002/hep.22694.
7
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Gastroenterology. 2008 Sep;135(3):821-9. doi: 10.1053/j.gastro.2008.05.044. Epub 2008 May 21.
8
Global challenges in liver disease.
Hepatology. 2006 Sep;44(3):521-6. doi: 10.1002/hep.21347.
9
Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
J Med Virol. 2006 Sep;78(9):1190-7. doi: 10.1002/jmv.20680.
10
Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
J Viral Hepat. 2006 May;13(5):311-5. doi: 10.1111/j.1365-2893.2005.00685.x.
Zotero 插件